Biotech Values

[oc631]

It is quite possible that ENTA acquisition discussions are taking place already and these discussions are not going well.

Discussions are not going well between ABBV and ENTA or not going well amongst the ENTA BOD? Ousting directors could be one way to settle an argument. Investors banking on a sale of the company may look at this as a negative event and an attempt by Luly to keep the company independent. I personally see value in the company regardless of outcome.


You made statements you claim are factual. Do you have an inside source on what's going on at ENTA?